Results 131 to 140 of about 20,405 (323)

Designing Silver Nanoparticles for Detecting Levodopa (3,4-Dihydroxyphenylalanine, L-Dopa) Using Surface-Enhanced Raman Scattering (SERS) [PDF]

open access: gold, 2019
Rafael Jesus Gonçalves Rubira   +8 more
openalex   +1 more source

Contralateral Spread of Asymmetrical Tremor in Parkinson's Disease

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinsonian tremor usually starts asymmetrically. The mid‐term prognosis of this lateralized tremor is unknown, as is the development of tremor in the contralateral arm. Objective To investigate the occurrence of contralateral tremor in the Parkinson's Progression Marker Initiative database, with data available for 7 years ...
Jacopo Pasquini   +4 more
wiley   +1 more source

Managing Dystonia in Partington Syndrome

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Bilateral focal hand dystonia is an almost pathognomonic sign of Partington syndrome, frequently accompanied by intellectual disability and oromotor dyspraxia. However, a few studies have focused on the treatment of this focal dystonia, making patient management uncertain.
Emilie Pichon   +13 more
wiley   +1 more source

Electrochemical and Redox Strategies for the Synthesis of Catecholamine- and Dihydroxynaphthalene-Based Materials: A Comparative Review

open access: yesElectrochem
Melanins are multifunctional biopolymers with unique properties, ranging from UV and radiation protection to antioxidant activity and metal chelation, making them highly attractive for biomedical applications.
Chloé Laporte, Vincent Ball
doaj   +1 more source

Directed Evolution of an Improved Aminoacyl‐tRNA Synthetase for Incorporation of L‐3,4‐Dihydroxyphenylalanine (L‐DOPA)

open access: green, 2021
Ross Thyer   +5 more
openalex   +2 more sources

High Cerebrospinal DOPA Decarboxylase Level Predicts Cognitive Decline in Parkinson's Disease

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background DOPA decarboxylase (DDC) in cerebrospinal fluid (CSF) is an emerging Parkinson's disease (PD) biomarker, but its association with nonmotor symptoms is unclear. Objectives We aimed to determine if baseline DDC was associated with future cognitive decline in PD.
Andrea Sturchio   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy